LONDON (Alliance News) - 4D Pharma PLC said Tuesday tests have shown its MRx0518 cancer treatment has "strong immuno-stimulatory effects".
Researchers at 4D demonstrated that MRx0518 - focused on melanoma and non-small cell lung cancer - had stimulated both the innate and adaptive immune systems. This had also identified the bacterial flagellin - a specific component of the MRx0518 bacterium - which interacts with the TLR5 host receptor associated with the response of the body to cancer.
The findings were published in the Scientific Reports journal under the title: "The flagellin of candidate live biotherapeutic Enterococcus gallinarum MRx0518 is a potent immunostimulant".
"This publication exemplifies our commitment to conducting leading microbiome research and further highlights the importance of a strain-level understanding of function and mechanism in selecting live biotherapeutic candidates for clinical development", 4D Chief Scientific Officer Alex Stevenson said.
Shares in 4D were untraded at 109.75 pence on Tuesday.